With data from the registry KiProReg, this study included 294 patients receiving PBT for intracranial tumors. Patients with 18 tumor entities were included. The most frequent ones were ependymomas and medulloblastomas. The 3-year OS of the whole cohort was 82.7%, PFS 67.3%, and LC 79.5%. Seventeen patients developed grade 3 adverse events of the CNS during long-term follow-up and two patients developed vision loss (grade 4). The authors concluded that PBT produced promising outcomes and long-term side effects were within the expected ranges.